CLINICAL_TRIALS
trial_result
· 2019-08-28
Clinical Trial Update: An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine [Phase 3]
Summary
An extension Phase 3 study assessing the long-term safety and tolerability of ubrogepant for migraine with or without aura has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Allergan | Conditions: Migraine, With or Without Aura | Phase 3 | Status: COMPLETED | Results posted: 2019-08-28